Monocyte-derived DC therapies programmed for robust IL-12p70 production have been associated with favorable outcomes in cancer clinical trials. However, clinical responses remain inconsistent even under standardized protocols, and the cellular basis for this variability is unknown. We leveraged single-cell multiomics to characterize two widely used DC platforms, the high-IL-12p70-producing α-Type-1-polarized DC (αDC1) and the IL-12p70-deficient DC induced in the presence of PGE 2 (PGE2-DC), at baseline and following rhCD40L activation. DC generated from 7 healthy participants representing the spectrum of rhCD40L-induced IL-12p70 production were profiled by transcriptome analysis with 42-plex surface proteomics, multiplex ELISA, and ELISpot quantification of IL-12p70-producing cells. While αDC1 and PGE2-DC distinctly responded to rhCD40L, αDC1 alone comprised 3 transcriptionally and phenotypically distinct subpopulations in resting and stimulated states. Only a limited fraction of αDC1 coexpressed IL12A and IL12B (IL-12p70 producers), confirmed by ELISpot at the protein level. The distribution of αDC1 subclusters varied markedly between individuals and correlated with bulk cytokine and chemokine secretion profiles. Magnetic enrichment on the surface marker CD116 yielded αDC1 fractions that differentially primed naïve CD4 + T cells, demonstrating these subpopulations are functionally divergent and separable. This heterogeneity may underlie inconsistent clinical outcomes, providing a rationale for subcluster-based release criteria and patient stratification.
Allison E. DePuyt, Peter E. J. Shoucair, Holly A. Bilben, Jeremy Martinson, Bernard J.C. Macatangay, Charles Rinaldo, Pawel Kalinski, Robbie B. Mailliard